When was Navega Therapeutics founded?

Navega Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Navega Therapeutics located?

Navega Therapeutics is headquartered in San Diego, United States.

Who is the current CEO of Navega Therapeutics?

Ana Moreno of Navega Therapeutics. They have also founded 1 company.

How many employees does Navega Therapeutics have?

As of Jul 01, 2024, the latest employee count at Navega Therapeutics is 4.

Is Navega Therapeutics a funded company?

Navega Therapeutics is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 10, 2019.

When was the latest funding round of Navega Therapeutics?

Navega Therapeutics' latest funding was a $***** Grant (prize money) round on Apr 16, 2025, with participation from 1 investor.

Where does Navega Therapeutics rank among its competitors?

Navega Therapeutics ranks 2098th amongst 3170 active competitors, of which 1090 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Navega Therapeutics, which secured $4.28M in Apr, 2025.

Who are the top competitors of Navega Therapeutics?

Navega Therapeutics' top competitors include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Among them, Navega Therapeutics secured the most recent funding round in April, 2025.

Navega Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Navega Therapeutics is a funded company based in San Diego (United States), founded in 2018 by Ana Moreno, Prashant Mali and Fernando Aleman. It operates as a Developer of gene therapy products for chronic pain management. Navega Therapeutics has raised an undisclosed amount in funding. The company has 3170 active competitors, including 1090 funded and 788 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, argenx and Sana Biotechnology.

Company Details

Developer of gene therapy products for chronic pain management. The company's novel gene therapy platform to target and imitate the patients with a mutation in the genome where no pain is felt., and apply it to treat pain.

Key Metrics

Founded Year

2018

Location

San Diego, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Apr 16, 2025, $*****

Investors

HHS

Ranked

2098^th among 3170 active competitors

Employee Count

4 as on Jul 01, 2024

Similar Companies

Sana Biotechnology & 976 more

View Navega Therapeutics' full profile

Navega Therapeutics has raised funding over 6 rounds. Its first funding round was on Sep 10, 2019. Its latest funding round was a Grant (prize money) round on Apr 16, 2025 for $*****. 1 investor participated in its latest round. Navega Therapeutics has 1 institutional investor.

Here is the list of recent funding rounds of Navega Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 16, 2025	4298785	Grant (prize money)	3852546	7346388	4981697	9920105
Apr 10, 2025	8147067	Grant (prize money)	3077957	4169952	8699763	HHS
Sep 22, 2023	6665192	Grant (prize money)	3898995	5303944	1568532	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Navega Therapeutics's funding rounds and investors

The founders of Navega Therapeutics are Ana Moreno, Prashant Mali and Fernando Aleman. Ana Moreno is the CEO of Navega Therapeutics.

Here are the details of Navega Therapeutics' key team members:

Ana Moreno: Co-Founder & CEO of Navega Therapeutics.
Contact Info: 1 email address
Prashant Mali: Co-Founder of Navega Therapeutics.
Fernando Aleman: Co-Founder of Navega Therapeutics.
Contact Info: 1 email address

View details of Navega Therapeutics's Founder profiles and Board Members

Navega Therapeutics' employee count trend

Navega Therapeutics has 4 employees as of Jul 24. Here is Navega Therapeutics's employee count trend over the years:

Employee count trend for Navega Therapeutics

Uncover Navega Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Navega Therapeutics include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Here is the list of Top 10 competitors of Navega Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Omnes Capital & 20 others	76/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
6th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Wellington & 6 others	74/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
8th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
9th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
10th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	Hudson Bay Capital, GIC & 19 others	71/100
2098th	Navega Therapeutics 2018, San Diego (United States), Funding Raised	Developer of gene therapy products for chronic pain management	-	HHS	27/100